Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Phasebio Pharmaceuticals Inc
(NQ:
PHAS
)
0.0701
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Nov 2, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Phasebio Pharmaceuticals Inc
< Previous
1
2
3
4
Next >
PhaseBio Announces Interim Analysis of REVERSE-IT Phase 3 Trial Accepted for Late Breaking Science Presentation at the American Heart Association Scientific Sessions 2021
October 06, 2021
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
PhaseBio Appoints William D. Humphries to Board of Directors
September 15, 2021
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
PhaseBio Pharmaceuticals to Present at 23rd Annual H.C. Wainwright Global Investment Conference
August 31, 2021
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal
August 14, 2021
Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to...
Via
Talk Markets
PhaseBio Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
August 12, 2021
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial, Enabling Preparation of a BLA submission for Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor
August 12, 2021
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
PhaseBio Pharmaceuticals and SFJ Pharmaceuticals® Announce Approval of IND Application in China for Bentracimab
August 10, 2021
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
PhaseBio Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2021 on July 15
June 30, 2021
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
June 17, 2021
Gainers Midatech Pharma (NASDAQ:MTP) share...
Via
Benzinga
PhaseBio Stock Jumps On Bentracimab Commercialization Pact In Europe
June 17, 2021
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has entered into an exclusive licensing agreement with privately-held Alfasigma S.p.A for the commercialization of...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 17, 2021
Gainers Midatech Pharma (NASDAQ:MTP) shares moved upwards by 50.98% to $3.08 during Thursday's pre-market session. The company's market cap stands at $39.0 million...
Via
Benzinga
PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A for Commercialization of Bentracimab
June 17, 2021
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
PhaseBio Highlights Real-World Healthcare Cost and Bleeding Cost Data Featured at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Virtual 2021 Conference
May 20, 2021
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 19, 2021
Gainers Advaxis (NASDAQ:ADXS) shares increased by 27.34% to $0.62 during Wednesday's pre-market session. The company's market cap stands at $85.2 million. Lixte...
Via
Benzinga
PhaseBio Highlights Real-World Bleeding and Surgery Data Featured at The American College of Cardiology's 70th Annual Scientific Session
May 17, 2021
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
PhaseBio Reports First-Quarter 2021 Financial Results and Recent Business Highlights
May 13, 2021
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
May 11, 2021
Gainers Applied DNA Sciences (NASDAQ:APDN) shares rose 27.71% to $7.42 during Tuesday's regular session. Trading volume for Applied DNA Sciences's stock is 7.2...
Via
Benzinga
PhaseBio Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference
April 07, 2021
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.